TY  - BOOK
AU  - Deshmukh, Abhishek
TI  - Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006-2011)
SN  - 1522-1946
PY  - 2016///
KW  - *Endovascular Procedures
KW  - *Lower Extremity/bs [Blood Supply]
KW  - *Peripheral Arterial Disease/th [Therapy]
KW  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
KW  - *Platelet Glycoprotein GPIIb-IIIa Complex/ai [Antagonists & Inhibitors]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Amputation
KW  - Cross-Sectional Studies
KW  - Databases, Factual
KW  - Drug Costs
KW  - Endovascular Procedures/ae [Adverse Effects]
KW  - Endovascular Procedures/ec [Economics]
KW  - Endovascular Procedures/mo [Mortality]
KW  - Female
KW  - Hospital Costs
KW  - Hospital Mortality
KW  - Humans
KW  - Limb Salvage
KW  - Logistic Models
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Odds Ratio
KW  - Peripheral Arterial Disease/di [Diagnosis]
KW  - Peripheral Arterial Disease/ec [Economics]
KW  - Peripheral Arterial Disease/mo [Mortality]
KW  - Platelet Aggregation Inhibitors/ae [Adverse Effects]
KW  - Platelet Aggregation Inhibitors/ec [Economics]
KW  - Propensity Score
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Young Adult
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Observational Study
N1  - Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
N2  - BACKGROUND: There is paucity of data regarding the impact of GPI on the outcomes following peripheral endovascular interventions; CONCLUSIONS: Multivariate analysis revealed GPI use in peripheral endovascular interventions to be suggestive of an increase in composite end-point of in-hospital mortality and postprocedural complications, no impact on in-hospital mortality alone, significantly lower rate of amputation, and increase in hospitalization costs. © 2016 Wiley Periodicals, Inc; Copyright © 2016 Wiley Periodicals, Inc; METHODS: The study cohort was derived from Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database between the years 2006 and 2011. Peripheral endovascular interventions and GPI utilization were identified using appropriate ICD-9 Diagnostic and procedural codes. Two-level hierarchical multivariate mixed models were created. The study outcomes were: primary (in-hospital mortality and amputation studied separately) and secondary (composite of in-hospital mortality and postprocedural complications). Hospitalization costs were also assessed; OBJECTIVE: The aim of our study was to study the impact of glycoprotein IIb/IIIa inhibitors (GPI) on in-hospital outcomes; RESULTS: GPI utilization (OR, 95% CI, P-value) was independently predictive of lower amputation rates (0.36, 0.27-0.49, <0.001). There was no significant difference in terms of in-hospital mortality (0.59, 0.31-1.14, P 0.117), although GPI use predicted worse secondary outcomes (1.23, 1.03-1.47, 0.023). Following propensity matching, the amputation rate was lower (3.2% vs. 8%, P<0.001), while hospitalization costs were higher in the cohort that received GPI (
UR  - https://dx.doi.org/10.1002/ccd.26452
ER  -